schizophrenia
Conditions
Interventions
Aripiprazole once-monthly will be maintained at the same dose as baseline for 12 weeks.
Brexpiprazole will be augmented with aripiprazole once-monthly for 12 weeks
Sponsors
Department of Neuropsychiatry, Kansai Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Outpatients having a diagnose of schizophrenia or schizoaffective disorder according to ICD-10 Patients who have not been hospitalized in a psychiatric unit in the past 6 months Baseline total score 120 or less on the PANSS total score Having regularly and consecutively received aripiprazole once-monthly for at least 2 months Having provided written informed consent
Exclusion criteria
Exclusion criteria: Serious complication Active suicidal ideations or past suicide attempts Drug or alcohol abuse Pregnant or breast-feeding females mental retardation Using of oral aripiprazole or asenapine, blonanserin Having been judged as unsuitable for the study forin other reasons by an principal investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Positive and Negative Syndrome Scale (PANSS) from week 0 to week 12 | — |
Secondary
| Measure | Time frame |
|---|---|
| Remission rate, Clinical Global Impression-Severity scale (CGI-S), Drug Induced Extra-Pyramidal Symptoms Scale (DIEPSS), UKU Side Effect Scale(UKU), Barnes Akathisia Rating Scale (BARS), Epworth Sleepness Scale(ESS), body weight, Body Mass Index, blood biochemistry, Japanese Adult Reading Test (JART), electroencephalography | — |
Countries
Japan
Contacts
Public ContactYoshiteru Takekita
Kansai Medical University Department of Neuropsychiatry
Outcome results
None listed